---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-024426"
form_type: "8-K"
ticker: "BBLG"
cik: "0001419554"
company_name: "Bone Biologics Corp"
filed_at: "2024-06-20T23:59:59+00:00"
generated_at: "2026-06-01T03:20:31.440083+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# First two patients treated in pilot study of NB1 bone graft device for spine fusion

## Summary
- Two patients treated in Australia in multicenter pilot study evaluating NB1 (NELL-1+DBM) for TLIF in degenerative disc disease.
- Study targets 30 adult subjects; design reviewed by FDA Division of Orthopedic Devices to support US pivotal trial.
- Preclinical studies showed strong safety profile and fusion success; CEO cites $3 billion global spine fusion market opportunity.

## SEC filing metadata
- accession: 0001493152-24-024426
- form_type: 8-K
- ticker: BBLG
- cik: 0001419554
- company_name: Bone Biologics Corp
- filed_at: 2024-06-20T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1419554/000149315224024426/0001493152-24-024426-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1419554/000149315224024426/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-024426
- JSON: https://secwatch.observer/filing/0001493152-24-024426.json
- Plain text: https://secwatch.observer/filing/0001493152-24-024426.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.